Welcome!

News Feed Item

Nephros Reports 2016 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Anticipates 100% Year Over Year Growth in Medical Device Filters; Anticipates Reaching Cash Flow Positive in Three to Six Months

RIVER EDGE, NJ -- (Marketwired) -- 03/20/17 -- Nephros, Inc. (OTCQB: NEPH) (the "Company"), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF") system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months and full year ended December 31, 2016.

"In 2016, we continued to execute on our growth strategy, focusing on the expansion of our product portfolio and on enhancing our sales and marketing efforts," said Daron Evans, President and Chief Executive Officer of Nephros. "We launched the S100 Point of Use product line, and completed our regulatory submissions for the HydraGuard™ and EndoPur™ product lines, which will we expect to launch in the second quarter of 2017. Additionally, we have completed the development of our NanoGuard-E product that inserts into any existing Everpure filter manifold, a standard in the food service industry. We also completed the development of our upcoming lead filter."

"Our approximately 40% growth in product revenue in the fourth quarter of 2016, versus the third quarter of 2016, was a result of both the launch of the S100, and growth from our existing filter portfolio. We expect a similar increase in revenue as we launch the HydraGuard™ and EndoPur™ product lines. We believe that we will grow filters sales in our core markets by over 100% in 2017 versus 2016, and that we be able to reach cash flow positive in three to six months now that we are through the regulatory approval process."

Corporate Update

Hospital Infection Control Filter Market

In 2016, revenue from the hospital infection control market grew 30% versus 2015. We expect this growth rate to increase significantly in 2017, due to several factors, including fast-growing sales of the new S100 Point-of-Use filter, the planned launch of the HydraGuard™ in the second quarter of 2017, and the planned launch of a flushable version of the HydraGuard™, to be released in the third quarter of 2017.

Dialysis Water Filter Market

In 2016, revenue from the dialysis water filter market declined 19% versus 2015. We narrowed our dialysis water sales and marketing efforts to focus on polish filters for reverse osmosis ("RO") systems. We are planning to launch our EndoPur™ Endotoxin filter product line, which is targeted at large dialysis clinic RO systems, in the second quarter of 2017.

Commercial / Industrial Water Filter Market

We have been working with our customers and strategic distribution partners to better understand the potential for our products in the commercial and industrial sector. We have performed pilot tests in multiple areas of potential interest. We are beginning to focus on certain niche markets where we believe our products may add substantial value and expect a meaningful revenue contribution from the commercial / industrial water filter market in 2017.

Hemodiafiltration System

Vanderbilt University began treating patients with our hemodiafiltration ("HDF") systems early in 2017. For the foreseeable future, we intend to support Vanderbilt in any efforts to publish prospective and observational data resulting from the treatment of patients with HDF.

Financial Performance for the Year Ended December 31, 2016

Total revenues for the year ended December 31, 2016, were approximately $2,320,000 compared to approximately $1,944,000 for the year ended December 31, 2015.

Cost of goods sold was approximately $1,026,000 for the year ended December 31, 2016, compared to approximately $844,000 for the year ended December 31, 2015.

Research and development expenses were approximately $1,079,000, and $826,000, respectively, for the years ended December 31, 2016 and December 31, 2015. Depreciation and amortization expense was approximately $230,000 for the year ended December 31, 2016, compared to approximately $212,000 for the year ended December 31, 2015. Selling, general and administrative expenses were approximately $2,854,000 for the year ended December 31, 2016 compared to approximately $3,443,000 for the year ended December 31, 2015.

As of December 31, 2016, Nephros had cash and cash equivalents of approximately $275,000.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company's website at www.nephros.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." Such statements include statements regarding our expectations that our EndoPur and HydraGuard filters will significantly contribute to our projected revenue growth, our expected 2017 product revenue, our ability to grow revenue, our ability to become cash flow positive in 2017, our expectation of increased adoption of our ultrafiltration products, our expectation to deploy our HDF module to an additional dialysis clinic, our expectations for 510(k) approval of our products, the efficacy and intended use of our technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "forecasts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that: (i) we may not be able to continue as a going concern; (ii) we may not be able to obtain funding if and when needed or on terms favorable to us in order to continue operations and successfully implement our business plan; (iii) we face significant challenges in obtaining market acceptance of our products and sales growth in key geographic areas, which could adversely affect our potential sales and revenues; (iv) we face potential liability associated with the production, marketing and sale of our products including with respect to potential serious injuries, product-related deaths or product malfunctions, product recalls, product liability claims, class action lawsuits or other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products; (v) to the extent our products or marketing materials are found to violate any provisions of the U.S. Food Drug and Cosmetic Act or any other statutes or regulations then we could be subject to enforcement actions by the FDA or other governmental agencies; (vi) we are dependent on third party suppliers, manufacturers and distributors over whom we may not control; and (vii) we may not be able to secure or enforce adequate legal protection, including patent protection, for our products.

More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements contained in this press release, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our other periodic reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's website at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.


                        NEPHROS, INC. AND SUBSIDIARY

                        CONSOLIDATED BALANCE SHEETS

             (In Thousands, Except Share and Per Share Amounts)

                                                December 31,   December 31,
                                                    2016           2015
                                               -------------  -------------
                    ASSETS
Current assets:
Cash                                           $         275  $       1,248
Accounts receivable, net                                 388            397
Investment in lease, net-current portion                  27              -
Inventory, net                                           479            591
Prepaid expenses and other current assets                 95            228
                                               -------------  -------------
Total current assets                                   1,264          2,464
Property and equipment, net                               70             12
Investment in lease, net-less current portion             61              -
License and supply agreement, net                      1,262          1,473
Other asset                                               21             21
                                               -------------  -------------
Total assets                                   $       2,678  $       3,970
                                               =============  =============
     LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable                               $         585  $         652
Accrued expenses                                         240            237
Deferred revenue, current portion                         70             70
                                               -------------  -------------
Total current liabilities                                895            959
Unsecured long-term note payable, net of debt
 issuance costs and debt discount of $349                838              -
Long-term portion of deferred revenue                    278            347
                                               -------------  -------------
Total liabilities                                      2,011          1,306
                                               -------------  -------------

Commitments and Contingencies (Note 13)

Stockholders' equity:

Preferred stock, $.001 par value; 5,000,000
 shares authorized at December 31, 2016 and
 2015; no shares issued and outstanding at
 December 31, 2016 and 2015.                               -              -
Common stock, $.001 par value; 90,000,000
 shares authorized at December 31, 2016 and
 2015; 49,782,797 and 48,580,355 shares issued
 and outstanding at December 31, 2016 and
 December 31, 2015, respectively.                         50             49
Additional paid-in capital                           120,835        119,797
Accumulated other comprehensive income                    67             71
Accumulated deficit                                 (120,285)      (117,253)
                                               -------------  -------------
Total stockholders' equity                               667          2,664
                                               -------------  -------------
Total liabilities and stockholders' equity     $       2,678  $       3,970
                                               =============  =============



                        NEPHROS, INC. AND SUBSIDIARY

        CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

             (In Thousands, Except Share and Per Share Amounts)

                                                 Years Ended December 31,
                                               ----------------------------
                                                    2016           2015
                                               -------------  -------------
Net revenue:
Product revenues                               $       2,093  $       1,790
License, royalty and other revenues                      227            154
                                               -------------  -------------
Total net revenues                                     2,320          1,944
                                               -------------  -------------

Cost of goods sold                                     1,026            884
                                               -------------  -------------
Gross margin                                           1,294          1,060
                                               -------------  -------------
Operating expenses:
Research and development                               1,079            826
Depreciation and amortization                            230            212
Selling, general and administrative                    2,854          3,443
                                               -------------  -------------
Total operating expenses                               4,163          4,481
                                               -------------  -------------
Loss from operations                                  (2,869)        (3,421)
Change in fair value of warrant liability                  -          2,099
Warrant modification expense                               -         (1,761)
Interest expense                                        (172)           (42)
Interest income                                            5              -
Other income (expense), net                                4             37
                                               -------------  -------------
Net loss                                              (3,032)        (3,088)
Other comprehensive loss, foreign currency
 translation adjustments                                  (4)            (1)
                                               -------------  -------------
Total comprehensive loss                       $      (3,036) $      (3,089)
                                               =============  =============

Net loss                                       $      (3,032) $      (3,088)
Deemed dividend as a result of warrant
 modification                                              -            (73)
                                               -------------  -------------
Net loss attributable to common stockholders   $      (3,032) $      (3,161)
                                               =============  =============
Net loss per common share, basic and diluted   $       (0.06) $       (0.09)
                                               =============  =============
Weighted average common shares outstanding,
 basic and diluted                                48,583,165     34,780,506
                                               =============  =============

Contact:

Investor:
PCG Advisory Group
Kirin M. Smith
Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, will provide a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services ...
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and atten...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...